Another potential setback for the Johnson & Johnson COVID-19 vaccine – new study suggests single-dose vaccine may be less effective in fighting delta variant than other vaccines, The New York Times reported.
The highly contagious delta variant now accounts for 83% of new cases in the United States.
the study – first published in The Times – found that antibody levels in those who have received the Johnson & Johnson vaccine may be low enough to be less protective.
Dr Joshua Lenchus of Broward Health pointed out that the study has yet to be peer reviewed.
“I think the bottom line is that it shouldn’t deter anyone from getting the vaccine, whether it’s J&J, Pfizer or Moderna in the United States,” he said.
The study authors say the data suggests that those who received the single dose should consider receiving a second injection of one of the available vaccines.
“As previously reported, Phase 3 studies demonstrated that a single injection of the Johnson & Johnson COVID-19 vaccine was 85% effective in protecting against serious illness and offered complete protection against hospitalization and death,” a spokesperson for Johnson & Johnson said in a statement. declaration. “Although the data from Landau et al. provides insight into just one aspect of the immune response elicited by COVID-19 vaccines, the data does not speak to the full nature of immune protection. “
Laura Matheric and her husband actually received two injections of Johnson & Johnson as part of a study in February that has since opened.
“We just felt like two doses were probably better than one,” she said.
The research is in progress. Matheric returns in September for a blood test.
The latest news doesn’t change her feelings except to remind her that the pandemic is not over.
“I feel protected. My husband and I are very happy that we did the study, doing our part to help the science,” she said. “I just think this confirms the fact that masks, social distancing, and hand washing are the most reliable things to do right now.”
Johnson & Johnson’s full statement in response to the report:
As previously reported, Phase 3 studies demonstrated that a single injection of the Johnson & Johnson COVID-19 vaccine was 85% effective in protecting against serious illness and offered complete protection against hospitalization and death. Although the data from Landau et al. provides insight into just one aspect of the immune response elicited by COVID-19 vaccines, the data does not speak to the comprehensive nature of immune protection. The dual protective mechanisms against COVID-19 generated by the Johnson & Johnson COVID-19 vaccine, both neutralizing and non-neutralizing binding antibodies and multiple types of T cells, play a cooperative role in the fight against SARS VOC-2.
The complex nature of a strong immune response is further enhanced by intermediate results of a phase 1 / 2a substudy published in the New England Journal of Medicine (NEJM) (Barouch, et al) who demonstrated that the humoral (antibody) and cellular (T cell) immune responses generated by the single injection COVID-19 vaccine from Johnson & Johnson were strong and stable for eight months after vaccination, the duration evaluated at Date. The data showed that T cell responses – including the important CD8 + T cells that seek out and destroy infected cells – persisted over the eight-month period examined.
Additional Company data also demonstrated that Johnson & Johnson’s single-injection COVID-19 vaccine generated strong and persistent activity against the rapidly spreading Delta variant and other widespread SARS-CoV-2 viral variants.